Sterling Capital Management’s Vaxcyte PCVX Stock Holding History

Sterling Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$215K	Buy	3,775 +2,601	+222%	+$152K	﹤0.01%	1119
2026 Q2	$68.2K	Sell	1,174 -2,965	-72%	-$161K	﹤0.01%	1501
2026 Q1	$241K	Sell	4,139 -2,475	-37%	-$134K	﹤0.01%	1099
2025 Q4	$305K	Sell	6,614 -1,314	-17%	-$58.8K	0.01%	1182
2025 Q3	$286K	Buy	7,928 +4,532	+133%	+$150K	﹤0.01%	1210
2025 Q2	$110K	Buy	3,396 +3,266	+2,512%	+$107K	﹤0.01%	1340
2025 Q1	$4.91K	Buy	130 +4	+3%	+$320	﹤0.01%	2179
2024 Q4	$10.3K	Buy	126 +4	+3%	+$397	﹤0.01%	2146
2024 Q3	$13.9K	Buy	+122	New	+$11K	﹤0.01%	1505

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Sterling Capital Management's PCVX Position: Q3 2026 in Review

Sterling Capital Management increased its Vaxcyte (PCVX) stake by 222% in Q3 2026, buying an estimated $152K and bringing the position to 3,775 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Sterling Capital Management first reported a position in PCVX in Q3 2024 and has held it in 9 quarters since. The position peaked at $305K in Q4 2025. 167 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

Sterling Capital Management held 3,775 shares of Vaxcyte worth $215K as of Q3 2026.
Sterling Capital Management bought 2,601 Vaxcyte shares in Q3 2026, an estimated $152K.
Vaxcyte made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1119 holding.
Sterling Capital Management first reported a position in Vaxcyte in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Vaxcyte position peaked at $305K in Q4 2025.
167 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.